Clinical Trial Search

Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) — 6; 4 Participants

Primary: Change From Baseline in Mean Sitting Systolic Blood Pressure (MSSBP) — 114.7; -11.2 millimeters of mercury (mmHg)

Primary: VAS-anxiety Immediately After the Impromptu Speech Task — 54.3; 62.6 millimeters (units on a scale) — p=0.056

Primary: Atrial Fibrillation Recurrence — 2; 3; 7 Participants

Primary: Pembro Combo vs Chemo: Progression-free Survival (PFS) Using Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review…

Primary: Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE Version 4.03 — 4; 14; 29; 1 Participants

Primary: Growth Velocity — 13; 13.1 g kg-1 day-1

Primary: Proportion of Subjects Who Achieve American College of Rheumatology20 Response Rate — 0.7949; 0.7722; 0.7143; 0.7308 proportion of subjects — p=0.0001

Primary: Change in Time Spent in Drug-paired Room — 24.5; 6.2 seconds

Primary: Percent of Eyes With UCDVA of 20/20 or Better — 41 Eyes

Primary: Percentage of Participants Who Achieved a Point in Time Objective Response (Either Complete or Partial Response [CR or PR]) Prior to Surgery — 2; 0 Participants

Primary: Change From Baseline in Average Bristol Stool Form Scale (BSFS) Score Over 4 Weeks of Treatment Period — 5.89; 5.34; -1.25; -1.09 score on a scale

Primary: Change in Macular Drusen Volume — 0.05; 0.11; 20.0; 9.0 mm^3

Primary: Change From Baseline in the Total Score of the Montgomery Asberg Depression Rating Scale (MADRS) at 24 Hrs — -15.51; -12.98; -12.94; -7.27 Scores on a Scale — p=0.0013

Primary: Smoking Abstinence — 8.25; 12.35 percentage of participants